Stock Analysis on Net

IQVIA Holdings Inc. (NYSE:IQV)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 1, 2023.

Analysis of Profitability Ratios

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Profitability Ratios (Summary)

IQVIA Holdings Inc., profitability ratios

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Return on Sales
Gross profit margin
Operating profit margin
Net profit margin
Return on Investment
Return on equity (ROE)
Return on assets (ROA)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The financial data reveals several notable trends in profitability and efficiency measures over the five-year period from 2018 to 2022.

Gross Profit Margin
The gross profit margin showed a slight downward trend from 35.21% in 2018 to a low of 33.45% in 2021, before recovering modestly to 34.89% in 2022. This indicates a general stability in the company's ability to manage cost of goods sold relative to sales, with a minor compression in margins especially in the 2019-2021 interval, followed by a slight improvement.
Operating Profit Margin
Operating profit margin exhibited a more dynamic pattern, starting at 7.12% in 2018 and decreasing marginally to 6.44% in 2020. Thereafter, a significant improvement occurred with the margin increasing to 10.04% in 2021 and further to 12.48% in 2022. This suggests enhanced operational efficiency or favorable operating leverage effects in the latter years, possibly due to better expense control or revenue growth outpacing operational costs.
Net Profit Margin
The net profit margin followed a fluctuating trajectory, declining from 2.49% in 2018 to 1.72% in 2019, then rising slightly to 2.46% in 2020. Subsequently, it increased sharply to 6.96% in 2021 and reached 7.57% in 2022. This pattern aligns with the improvements seen in operating profit margins and may reflect both enhanced operational performance and improved control over non-operating expenses or tax benefits.
Return on Equity (ROE)
ROE demonstrated a marked upward trend over the period. Starting at a modest 3.86% in 2018, it slightly declined to 3.18% in 2019, then rebounded to 4.65% in 2020. The next two years show a steep increase to 15.99% in 2021 and 18.92% in 2022, indicating a significantly more effective use of shareholders' equity to generate profits. The substantial rise in 2021 and 2022 suggests either improved profitability, better financial leverage, or both.
Return on Assets (ROA)
ROA followed a similar pattern of initial decline and subsequent recovery and growth. It decreased from 1.15% in 2018 to 0.82% in 2019, then increased to 1.14% in 2020. Thereafter, it grew substantially to 3.91% in 2021 and 4.31% in 2022. This suggests improved overall asset utilization efficiency aligned with the enhanced profitability metrics observed during the latter years.

In summary, the company experienced a period of stagnation or minor decline in profitability and efficiency ratios during the early years (2018-2020), followed by a notable rebound and strong improvement from 2021 onwards. The increase in profit margins and returns indicates a positive shift in operational effectiveness and financial performance.


Return on Sales


Return on Investment


Gross Profit Margin

IQVIA Holdings Inc., gross profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Gross profit
Revenues
Profitability Ratio
Gross profit margin1
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Gross profit margin = 100 × Gross profit ÷ Revenues
= 100 × ÷ =

2 Click competitor name to see calculations.


Revenue Trends
The revenue figures indicate a consistent upward trend over the five-year period. Starting at approximately 10.41 billion USD in 2018, revenues increased annually to reach around 14.41 billion USD by the end of 2022. This represents a cumulative growth of roughly 38.4%, reflecting steady expansion in the company’s sales or service income.
Gross Profit Trends
Gross profit also showed a consistent increase in absolute terms over the same period. From about 3.67 billion USD in 2018, it rose to approximately 5.03 billion USD by the end of 2022. This upward trajectory is in line with the growth in revenues, indicating maintained or improved efficiency in managing cost of goods sold relative to revenue.
Gross Profit Margin Analysis
The gross profit margin, expressed as a percentage, demonstrates minor fluctuations but remains relatively stable around the mid-30s. Starting at 35.21% in 2018, it dipped slightly in the subsequent years, reaching a low of 33.45% in 2021 before recovering slightly to 34.89% in 2022. This pattern suggests that while the company has experienced revenue and gross profit growth, its cost structure fluctuated slightly, impacting profit margins. However, the margin has remained fairly consistent overall, indicating stable operational efficiency.
Insights and Summary
The data reveals that the company has successfully grown its top-line revenue and gross profit over the five years, with gross profits increasing proportionally to revenues. Despite some minor contraction in gross margin percentage during the middle years, the margin has largely stabilized, implying effective cost management relative to sales. This stability coupled with growth in revenue and gross profit suggests a positive operational performance with sustained profitability at the gross profit level.

Operating Profit Margin

IQVIA Holdings Inc., operating profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Income from operations
Revenues
Profitability Ratio
Operating profit margin1
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Operating Profit Margin, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Operating Profit Margin, Industry
Health Care

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Operating profit margin = 100 × Income from operations ÷ Revenues
= 100 × ÷ =

2 Click competitor name to see calculations.


Income from operations
The income from operations exhibited a fluctuating trend over the observed periods. Initially, it increased moderately from 741 million USD in 2018 to 777 million USD in 2019 but experienced a decline to 731 million USD in 2020. Subsequently, it showed a significant increase, reaching 1,393 million USD in 2021 and further rising to 1,799 million USD in 2022. This indicates a strong recovery and growth momentum in the later years.
Revenues
Revenues demonstrated steady growth throughout the period. Starting at 10,412 million USD in 2018, revenues increased consistently each year, reaching 11,088 million USD in 2019 and 11,359 million USD in 2020. The growth accelerated notably after 2020, rising to 13,874 million USD in 2021 and 14,410 million USD in 2022. The pattern reflects a stable and expanding top-line performance.
Operating profit margin
The operating profit margin showed a slight downward trend in the initial years, decreasing from 7.12% in 2018 to 7.01% in 2019 and further to 6.44% in 2020. However, the margin improved significantly thereafter, rising to 10.04% in 2021 and reaching 12.48% in 2022. This suggests enhanced operational efficiency and profitability in the most recent years.

Net Profit Margin

IQVIA Holdings Inc., net profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Net income attributable to IQVIA Holdings Inc.
Revenues
Profitability Ratio
Net profit margin1
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Net Profit Margin, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Net Profit Margin, Industry
Health Care

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Net profit margin = 100 × Net income attributable to IQVIA Holdings Inc. ÷ Revenues
= 100 × ÷ =

2 Click competitor name to see calculations.


Revenues
Revenues have shown a consistent upward trend over the analyzed period. From 2018 to 2022, revenues increased from approximately 10,412 million US dollars to 14,410 million US dollars, representing steady growth year-over-year. The largest annual increase occurred between 2020 and 2021.
Net Income Attributable to IQVIA Holdings Inc.
Net income displayed some fluctuations in the initial years, dropping from 259 million US dollars in 2018 to 191 million US dollars in 2019, and then recovering to 279 million US dollars in 2020. Following this, a significant increase occurred in 2021 and 2022, with net income rising sharply to 966 million US dollars and then to 1,091 million US dollars, indicating improved profitability in recent years.
Net Profit Margin
The net profit margin fluctuated in the early years, decreasing from 2.49% in 2018 to 1.72% in 2019, then increasing slightly to 2.46% in 2020. A notable improvement occurred in the last two years, with the margin rising substantially to 6.96% in 2021 and further to 7.57% in 2022. This reflects enhanced operational efficiency or higher profitability relative to revenues.
Overall Insights
Over the five-year period, the data indicates robust revenue growth accompanied by a marked improvement in net profitability. The substantial increases in both net income and net profit margin during the last two years suggest effective management of costs or increased high-margin business activities. The earlier fluctuations in net income and margin could reflect transitional challenges or investments that have since realized returns.

Return on Equity (ROE)

IQVIA Holdings Inc., ROE calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Net income attributable to IQVIA Holdings Inc.
Equity attributable to IQVIA Holdings Inc.’s stockholders
Profitability Ratio
ROE1
Benchmarks
ROE, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
ROE, Sector
Pharmaceuticals, Biotechnology & Life Sciences
ROE, Industry
Health Care

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
ROE = 100 × Net income attributable to IQVIA Holdings Inc. ÷ Equity attributable to IQVIA Holdings Inc.’s stockholders
= 100 × ÷ =

2 Click competitor name to see calculations.


Net Income Attributable to IQVIA Holdings Inc.
The net income demonstrates a fluctuating trend over the analyzed period. Initially, there is a decline from 259 million USD in 2018 to 191 million USD in 2019. Subsequently, the figure rises to 279 million USD in 2020, followed by a significant increase to 966 million USD in 2021. The upward trend continues into 2022, reaching 1,091 million USD. This pattern illustrates a period of volatility in earnings in the early years, succeeded by a strong and sustained profitability growth in the latter years.
Equity Attributable to IQVIA Holdings Inc.’s Stockholders
The equity value shows a gradual decline across the five-year span, starting at 6,714 million USD in 2018. It decreases slightly to 6,003 million USD in 2019 and remains relatively stable at around 6,000 million USD in 2020 and 2021. By 2022, equity further declines to 5,765 million USD. This pattern indicates a minor erosion in equity capital over time, despite the improvements observed in earnings.
Return on Equity (ROE)
The return on equity exhibits a marked increase throughout the years. From a low of 3.18% in 2019 (down from 3.86% in 2018), it rises to 4.65% in 2020, then sharply accelerates to 15.99% in 2021 and further to 18.92% in 2022. The significant increase in ROE aligns with the substantial growth in net income, indicating enhanced efficiency in generating profit from equity capital despite the slight decline in the equity base.
Overall Insights
The data reveals a company that experienced moderate earnings and equity stability initially but underwent a notable transformation in profitability starting in 2021. The sharp rise in net income and return on equity suggests operational improvements or favorable business conditions contributing to enhanced profitability. Meanwhile, the slight decrease in equity suggests possible share repurchases, dividend distributions, or other capital management activities that did not hinder profitability gains. The overall financial health appears to strengthen in terms of profitability, though the equity base requires monitoring to ensure sustained capital adequacy.

Return on Assets (ROA)

IQVIA Holdings Inc., ROA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Net income attributable to IQVIA Holdings Inc.
Total assets
Profitability Ratio
ROA1
Benchmarks
ROA, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
ROA, Sector
Pharmaceuticals, Biotechnology & Life Sciences
ROA, Industry
Health Care

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
ROA = 100 × Net income attributable to IQVIA Holdings Inc. ÷ Total assets
= 100 × ÷ =

2 Click competitor name to see calculations.


The financial data reveals several notable trends over the five-year period ending December 31, 2022. The net income attributable to the entity shows variability across the years, starting at 259 million US dollars in 2018, experiencing a decline in 2019 to 191 million, followed by a recovery to 279 million in 2020. A significant increase occurred in 2021, where net income rose sharply to 966 million, continuing with further growth to 1091 million in 2022. This indicates a substantial improvement in profitability in the latter two years compared to earlier periods.

Total assets demonstrate a steady but moderate upward trend throughout the period. Assets increased from 22,549 million US dollars in 2018 to 25,337 million by the end of 2022. The growth in assets is relatively consistent year-over-year without any notable volatility.

Return on Assets (ROA) closely mirrors the pattern observed in net income, reflecting profitability relative to the asset base. The ROA starts at 1.15% in 2018, declines to 0.82% in 2019, then rises slightly to 1.14% in 2020. A pronounced increase is observed in 2021 when ROA jumps to 3.91%, and it improves further to 4.31% in 2022. This suggests enhanced efficiency in generating profits from assets during the most recent years.

Summary of Major Trends:
- Net income showed variability initially but improved substantially in the last two years, nearly quadrupling from 2020 to 2022.
- Total assets increased steadily, reflecting gradual growth in the asset base over the period without sharp fluctuations.
- ROA experienced a decline in 2019 but increased markedly in 2021 and 2022, indicating a strong recovery and better asset utilization.
- The correlation between rising net income and improved ROA suggests enhanced profitability and operational efficiency in recent years.